Physician profile
Gregg Silverman
NPI 1952327009
$106,159.38
in general payments reported to CMS, 2019-2025
16 companies · $8,992 in 2025
The $8,992 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $9,895 · 2021: $4,644 · 2022: $21K · 2023: $2,873 · 2024: $2,089 · 2025: $8,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,865.00 |
| Food and Beverage | $1,088.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28,918.63 | 2019-2024 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $22,277.00 | 2019-2025 | Orencia, Sotyktu |
| Gilead Sciences, INC. | $21,013.26 | 2019-2020 | |
| Genentech, INC. | $12,609.30 | 2019-2024 | Ocrevus, Lunsumio, Gazyva |
| Genentech USA, INC. | $5,811.73 | 2020-2025 | Gazyva |
| F. Hoffmann-La Roche Ag | $5,750.00 | 2022 | |
| Argenx US, INC. | $5,000.00 | 2025 | |
| Abbvie INC. | $2,152.80 | 2019-2025 | |
| Genzyme Corporation | $1,215.00 | 2020 | |
| Ucb, INC. | $314.34 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $299.78 | 2019 | |
| Biogen, INC. | $250.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $225.77 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $127.54 | 2019 | |
| Lilly USA, LLC | $125.08 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $69.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.